ReviewThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2020
Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls.
Review in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Review
- Quantitative Three-Dimensional Color Power Angiography Parameters Predict Response to Locally Injected Bleomycin in Infantile Hemangioma.Diagnostics (Basel, Switzerland) · 2025Article
- Multisystem Infantile Hemangiomatosis with Cutaneous, Hepatic, and Splenic Involvement.Pediatric reports · 2025Article
- Effective Management of Tongue Hemangioma Using Boiling 3% Hypertonic Saline Injections: A Case Report from a Resource-Limited Setting.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Atypical development and swift resolution of an ulcerated hemangioma: a case report.Journal of medical case reports · 2025Article
- Article
- Vulvar Hemangioma: A Review.Diagnostics (Basel, Switzerland) · 2025Review
- Nanotechnology in Infantile Hemangioma Management.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- A Rare Nasopharyngeal Hemangioma Presenting as Recurrent Cyanotic Apnea in a Neonate: A Case Report and Literature Review.Case reports in medicine · 2025Article
- New Insights into Cervicofacial Vascular Anomalies.Journal of clinical medicine · 2024Review
- Infantile Hemangiomas of the Head and Neck: A Single-Center Experience.Children (Basel, Switzerland) · 2024Article
- Infantile hemangiomas screening modalities for primary care physicians.Pediatric investigation · 2023Review
- Article
- Infantile Haemangioma in the Romanian Paediatric Population-Characteristics and Therapeutic Approaches.Children (Basel, Switzerland) · 2023Article
- Infantile hemangioma models: is the needle in a haystack?Journal of translational medicine · 2023Review
- Long non-coding RNA breast cancer-associated transcript 54 sponges microRNA-1269b to suppress the proliferation of hemangioma-derived endothelial cells.Bioengineered · 2022Article
- [The most common benign cutaneous neoplasms of vascular, muscular, and adipose tissue and their treatment].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2022Review
- Medical Management of Infantile Hemangiomas: An Update.Paediatric drugs · 2022Review
- Article
- Itraconazole therapy for infant hemangioma: Two case reports.World journal of clinical cases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hemangioma (IH) is the most common vascular tumor of infancy, affecting as many as 5% to 10% of all infants. The exact cause is unclear, but specific risk factors, such as low birth weight, prematurity, female sex, white race, and family history are associated with IH development. Most IHs are benign and self-resolving, but a small subset of patients with IHs are at risk of severe or life-threatening outcomes. Systemic and topical β-blockers are effective and safe for use in pediatric patients and considered first-line treatment for both complicated and uncomplicated IHs. Recently published guidelines provide a thorough review of IH and management. This article focuses on IH pharmacotherapy and provides practice pearls to support health care providers in IH medication management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.